Altimmune, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALT Nasdaq 2830 altimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Altimmune, Inc.

Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect? - Dec 11th, 2025 7:55 am
Altimmune Announces CEO Transition and Succession Plan - Dec 1st, 2025 5:30 am
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference - Nov 26th, 2025 5:30 am
Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know - Nov 25th, 2025 7:55 am
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 - Nov 11th, 2025 6:51 am
Altimmune price target lowered to $14 from $15 at Citizens JMP - Nov 8th, 2025 4:05 am
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 - Nov 7th, 2025 6:05 am
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates - Nov 6th, 2025 5:00 am
Altimmune to Participate in Two Upcoming Investor Conferences - Nov 5th, 2025 5:30 am
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder - Nov 3rd, 2025 5:30 am
3 Explosive Stocks With High Short Interest - Oct 31st, 2025 9:18 am
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 - Oct 30th, 2025 5:30 am
Pleasing Signs As A Number Of Insiders Buy Altimmune Stock - Oct 8th, 2025 4:27 am
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide - Sep 29th, 2025 5:30 am
Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer - Sep 15th, 2025 5:30 am
Altimmune to Participate in Upcoming Investor Conferences - Aug 26th, 2025 5:30 am
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) - Aug 19th, 2025 5:30 am
Altimmune First Half 2025 Earnings: Beats Expectations - Aug 14th, 2025 5:31 am
Individual investors account for 51% of Altimmune, Inc.'s (NASDAQ:ALT) ownership, while institutions account for 48% - Aug 13th, 2025 5:30 am
Altimmune Inc (ALT) Q2 2025 Earnings Call Highlights: Strong Cash Position and Promising Drug ... - Aug 13th, 2025 1:07 am